Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

1 min read

Selexis to Speak on Designer CHO Cell Lines for Difficult-to-Express Proteins at the 2012 Protein Engineering (PEGS) Summit

Apr 27, 2012 1:59:55 PM

Geneva, Switzerland (PRWEB) April 26, 2011 – Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today the Company’s chief technology officer, Armelle Gaussin, PhD, will be speaking on Designer Cell Lines for Difficult-to-Express Proteins at the 2012 PEGS Summit on Wednesday, May 2, 2012, at the Boston Park Plaza Hotel & Towers in Boston, Massachusetts. Selexis will also be exhibiting at the conference, April 30 – May 4, 2012.

Dr. Gaussin’s lecture, “Developing the Next Generation Designer Cell Lines as a Customized Approach for Optimized Therapeutic Protein Production” is part of the Engineering Antibodies track. Conference attendees can hear Dr. Gaussin’s lecture on Wednesday, May 2 at 11:40 AM.

Lecture Abstract:
The Chinese Hamster Ovary cell line is the predominant host for the production of therapeutic proteins. However, its capacity to provide high levels of certain classes of products such as fusion proteins remains limited. In order to overcome the specific expression bottlenecks associated with these difficult-to-express proteins, we have developed new designer CHO cell lines. These next generation cell lines have been metabolically engineered to over-express key components of the cell secretion network.

Additionally, conference attendees can meet Selexis representatives at Booth 7, April 30 – May 4. To schedule meetings in advance, please contact Selexis at

Registration for the PEGS conference is required. For more information, visit

Topics: 2012